by HBOT News | Apr 21, 2020 | Clinical Trials, COVID-19, HBOT Research
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic.So far, no
specific treatment has proven efficacy. Recent case series reported the use of Hyperbaric
Oxygen Therapy (HBOT) on 5 severe COVID-19 patients who developed respiratory insufficiency.
HBOT mechanisms of tissue oxygenation and anti-inflammatory effect may explain these
findings.
The purpose of the current study is the evaluate the efficacy of HBOT in moderate-severe
COVID-19 patients in a randomized controlled manner.
by HBOT News | Apr 9, 2020 | Clinical Trials, COVID-19, HBOT Research
Several patients with hypoxaemic SARS-CoV2 pneumonia were able to benefit from hyperbaric oxygen treatment (HBOT) in China. In a clinical case published in the Chinese journal of hyperbaric medicine, treatment with repeated HBO sessions prevented admission to intensive care unit with mechanical ventilation in a patient aged 69 who presented with signs of respiratory decompensation. HBOT is the most powerful oxygenation modality in the body today. HBOT can dramatically increase the amount of dissolved oxygen in the blood. HBOT not only promotes blood transport but also its tissue delivery. Furthermore, HBOT has specific immunomodulatory properties, both humoral and cellular, making it possible, for example, to reduce the intensity of the inflammatory response and to stimulate antioxidant defenses by repeating sessions. A virucidal capacity of HBOT might also be involved. HBOT is generally regarded as safe with very few adverse events.
by HBOT News | Apr 7, 2020 | Clinical Trials, COVID-19, HBOT Research
Patients who meet inclusion criteria will be randomized into treatment vs control group.
Treatment groups will undergo Hyperbaric Oxygen Therapy (HBOT) and compared to the control
group.
by HBOT News | Mar 30, 2020 | Clinical Trials, COVID-19, HBOT Research
Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patients with respiratory distress at NYU Winthrop Hospital. All patients prior to the clinical application of HBOT will be evaluated by the primary care team and hyperbaric physician. After the intervention portion of this study, a chart review will be performed to compare the outcomes of intervention patients versus patients who received standard of care.
